PAPZIMEOS hits profitability in first full launch year; survival now depends on sustaining revenue through EMA decision and cash flow break-even

Precigen is a commercial-stage biopharmaceutical company whose approved lead product, PAPZIMEOS, is a gene therapy that treats recurrent respiratory papillomatosis, a chronic airway disease.

PAPZIMEOS, an intratumoral gene-immunotherapy for recurrent respiratory papillomatosis, a chronic airway disease requiring repeated surgical debridement, reached $53M in Q2 2026 revenue and its first profitable quarter. The thesis holds if PAPZIMEOS revenue sustains cash flow break-even by year-end 2026, eliminating dilutive financing before the EMA decision. Key risk is revenue deceleration: the addressable RRP population is rare, and peak penetration could plateau faster than the commercial ramp implies.